Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

First results of a head-to-head trial of acalabrutinib versus ibrutinib in...

Dr John Byrd - The Ohio State University, Columbus, USA

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )

Breast cancer roundup from ASCO 2021

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

Prof John Allan - Weill Cornell Medicine, New York, USA

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL ( Prof John Allan - Weill Cornell Medicine, New York, USA )

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic...

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele...

EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )

OncoAlert and ecancer ASCO roundup - Day 4 and 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 4 and 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed...

Prof Neeraj Agarwal - Huntsman Cancer Institute, University of Utah, Salt Lake...

ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC ( Prof Neeraj Agarwal - Huntsman Cancer Institute, University of Utah, Salt Lake City, USA )

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5...

Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The...

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )

Developments in metastatic hormone-sensitive prostate cancer

Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura...

Developments in metastatic hormone-sensitive prostate cancer ( Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura-Maria Krabbe )

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP...

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

More from ecancer